Clinical features of neuroendocrine prostate cancer.
Aggressive variant
Neuroendocrine prostate cancer
Small-cell carcinoma
Treatment resistance
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
22
04
2019
revised:
18
07
2019
accepted:
09
08
2019
pubmed:
17
9
2019
medline:
9
6
2020
entrez:
17
9
2019
Statut:
ppublish
Résumé
Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may arise de novo or in patients previously treated with hormonal therapies for prostate adenocarcinoma as a mechanism of resistance. Despite being important to recognise, the clinical features of NEPC are poorly defined and could help guide when to perform a biopsy to look for NEPC histologic transformation. We reviewed baseline, treatment and outcome data of 87 patients with metastatic prostate cancer and tumour biopsy confirming NEPC histology. Forty-seven (54.0%) NEPC cases presented de novo, and 40 (46.0%) were therapy-related (t-NEPC). Thirty-six (41.4%) were classified as pure small-cell carcinoma, and 51 (58.6%) demonstrated mixed features with both small-cell carcinoma and adenocarcinoma present. Genomic data were available for 47 patients. The median age at time of NEPC was 68.1 years, median prostate-specific antigen (PSA) was 1.20 ng/ml (0.14 ng/mL small-cell carcinoma, 1.55 ng/mL mixed carcinoma) and sites of metastases included bone (72.6%), lymph node (47.0%), and viscera (65.5%). Median time from adenocarcinoma to t-NEPC diagnosis was 39.7 months (range, 24.5-93.8) with a median of two lines of prior systemic therapy. Platinum chemotherapy was used to treat 57.5% of patients, with a median progression-free survival of 3.9 months. Small-cell carcinoma was associated with worse overall survival (OS) than mixed histology (8.9 months from NEPC diagnosis versus 26.1 months, P < 0.001). Median OS of de novo NEPC was shorter than that of t-NEPC (16.8 months from prostate cancer diagnosis versus 53.5 months, P = 0.043). An average PSA rise per month of ≤0.7 ng/ml before t-NEPC; elevated lactate dehydrogenase levels, RB1 and TP53 loss and liver metastases were poor prognostic features. We describe the clinical features of a cohort of patients with NEPC. These characteristics may inform future diagnostic strategies.
Sections du résumé
BACKGROUND
Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may arise de novo or in patients previously treated with hormonal therapies for prostate adenocarcinoma as a mechanism of resistance. Despite being important to recognise, the clinical features of NEPC are poorly defined and could help guide when to perform a biopsy to look for NEPC histologic transformation.
METHODS
We reviewed baseline, treatment and outcome data of 87 patients with metastatic prostate cancer and tumour biopsy confirming NEPC histology. Forty-seven (54.0%) NEPC cases presented de novo, and 40 (46.0%) were therapy-related (t-NEPC). Thirty-six (41.4%) were classified as pure small-cell carcinoma, and 51 (58.6%) demonstrated mixed features with both small-cell carcinoma and adenocarcinoma present. Genomic data were available for 47 patients.
RESULTS
The median age at time of NEPC was 68.1 years, median prostate-specific antigen (PSA) was 1.20 ng/ml (0.14 ng/mL small-cell carcinoma, 1.55 ng/mL mixed carcinoma) and sites of metastases included bone (72.6%), lymph node (47.0%), and viscera (65.5%). Median time from adenocarcinoma to t-NEPC diagnosis was 39.7 months (range, 24.5-93.8) with a median of two lines of prior systemic therapy. Platinum chemotherapy was used to treat 57.5% of patients, with a median progression-free survival of 3.9 months. Small-cell carcinoma was associated with worse overall survival (OS) than mixed histology (8.9 months from NEPC diagnosis versus 26.1 months, P < 0.001). Median OS of de novo NEPC was shorter than that of t-NEPC (16.8 months from prostate cancer diagnosis versus 53.5 months, P = 0.043). An average PSA rise per month of ≤0.7 ng/ml before t-NEPC; elevated lactate dehydrogenase levels, RB1 and TP53 loss and liver metastases were poor prognostic features.
CONCLUSIONS
We describe the clinical features of a cohort of patients with NEPC. These characteristics may inform future diagnostic strategies.
Identifiants
pubmed: 31525487
pii: S0959-8049(19)30471-X
doi: 10.1016/j.ejca.2019.08.011
pmc: PMC6803064
mid: NIHMS1050555
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-18Subventions
Organisme : NCI NIH HHS
ID : P50 CA090381
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211024
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA210989
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA194547
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
Clin Cancer Res. 2013 Jul 1;19(13):3621-30
pubmed: 23649003
Ann Oncol. 2011 Nov;22(11):2476-81
pubmed: 21436186
Am J Surg Pathol. 2014 Jun;38(6):756-67
pubmed: 24705311
Ann Oncol. 2009 Apr;20(4):703-8
pubmed: 19179557
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Eur Urol. 2018 Feb;73(2):178-211
pubmed: 28655541
Clin Cancer Res. 2014 Jun 1;20(11):2846-50
pubmed: 24727321
Cancer Cell. 2006 Oct;10(4):321-30
pubmed: 17010675
Mol Cancer Res. 2019 Jun;17(6):1235-1240
pubmed: 30918106
J Clin Oncol. 2002 Jul 15;20(14):3072-80
pubmed: 12118020
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
Cancer Cell. 2017 Oct 9;32(4):474-489.e6
pubmed: 29017058
Clin Cancer Res. 2016 Mar 15;22(6):1520-30
pubmed: 26546618
Science. 2017 Jan 6;355(6320):78-83
pubmed: 28059767
J Clin Oncol. 2018 Aug 20;36(24):2492-2503
pubmed: 29985747
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
J Clin Oncol. 2012 Dec 20;30(36):e386-9
pubmed: 23169519
NPJ Genom Med. 2016;1:
pubmed: 28781886
Science. 2017 Jan 6;355(6320):84-88
pubmed: 28059768
Am J Surg Pathol. 2008 Jan;32(1):65-71
pubmed: 18162772
Cancer Discov. 2011 Nov;1(6):487-95
pubmed: 22389870
JAMA Oncol. 2015 Jul;1(4):466-74
pubmed: 26181256
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148